These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28727604)

  • 1. Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
    Kovalchin J; King B; Masci A; Hopkins E; Fry J; Hou J; Li C; Tenneson K; Weber S; Wolfe G; Collins K; Furfine ES
    Eye Contact Lens; 2018 May; 44(3):170-181. PubMed ID: 28727604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
    Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
    Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis.
    Goldstein MH; Tubridy KL; Agahigian J; Furfine E; Magill M; Kovalchin J; Golden K; Zarbis-Papastoitsis G; Soong F; Salapatek AM; Sternberg G; Celniker A
    Eye Contact Lens; 2015 May; 41(3):145-55. PubMed ID: 25915834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
    Goldstein MH; Martel JR; Sall K; Goldberg DF; Abrams M; Rubin J; Sheppard J; Tauber J; Korenfeld M; Agahigian J; Durham TA; Furfine E
    Eye Contact Lens; 2017 Sep; 43(5):287-296. PubMed ID: 27466718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a superior cytokine antagonist for topical ophthalmic use.
    Hou J; Townson SA; Kovalchin JT; Masci A; Kiner O; Shu Y; King BM; Schirmer E; Golden K; Thomas C; Garcia KC; Zarbis-Papastoitsis G; Furfine ES; Barnes TM
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3913-8. PubMed ID: 23431173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease.
    Okanobo A; Chauhan SK; Dastjerdi MH; Kodati S; Dana R
    Am J Ophthalmol; 2012 Jul; 154(1):63-71. PubMed ID: 22541929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
    Chung JK; Spencer E; Hunt M; McCauley T; Welty D
    J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
    Yamada J; Zhu SN; Streilein JW; Dana MR
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
    Liu S; Dozois MD; Chang CN; Ahmad A; Ng DL; Hileeto D; Liang H; Reyad MM; Boyd S; Jones LW; Gu FX
    Mol Pharm; 2016 Sep; 13(9):2897-905. PubMed ID: 27482595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Porphyrin Antioxidant Protects Against Ocular Surface Pathology in a Novel Rabbit Model for Particulate Matter-Induced Dry Eye Disease.
    Ghosh AK; Bacellar-Galdino M; Iqbal S; Pappenhagen NE; Kaja S
    J Ocul Pharmacol Ther; 2022 May; 38(4):294-304. PubMed ID: 35384749
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of topical immunomodulatory interleukin 1 receptor antagonist therapy on corneal healing in New Zealand white rabbits (Oryctolagus cunniculus) after photorefractive keratectomy.
    Davies BW; Panday V; Caldwell M; Scribbick F; Reilly CD
    Arch Ophthalmol; 2011 Jul; 129(7):909-13. PubMed ID: 21746982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of topical infliximab in a mouse model of experimental dry eye.
    Li Z; Choi W; Oh HJ; Yoon KC
    Cornea; 2012 Nov; 31 Suppl 1():S25-31. PubMed ID: 23038030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.
    Tang-Liu DD; Acheampong A
    Clin Pharmacokinet; 2005; 44(3):247-61. PubMed ID: 15762768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular pharmacokinetics profile of different indomethacin topical formulations.
    Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
    Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
    Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.